Scholar Rock (NASDAQ:SRRK) Given New $58.00 Price Target at Wedbush

Scholar Rock (NASDAQ:SRRK) had its target price increased by Wedbush from $56.00 to $58.00 in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other brokerages have also weighed in on SRRK. Truist Financial raised their target price on Scholar Rock from $44.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Citigroup raised their price objective on shares of Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, January 22nd. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday, March 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Scholar Rock currently has a consensus rating of “Buy” and a consensus target price of $54.93.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $49.35 on Wednesday. The stock has a market capitalization of $5.67 billion, a P/E ratio of -14.39 and a beta of 0.70. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.41. Scholar Rock has a 1 year low of $22.71 and a 1 year high of $50.50. The firm has a 50 day moving average of $45.17 and a 200-day moving average of $40.68.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period last year, the firm earned ($0.64) EPS. As a group, sell-side analysts anticipate that Scholar Rock will post -2.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other Scholar Rock news, insider Mo Qatanani sold 14,898 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $46.71, for a total transaction of $695,885.58. Following the transaction, the insider directly owned 85,660 shares in the company, valued at approximately $4,001,178.60. This represents a 14.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Vikas Sinha sold 16,755 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total transaction of $715,438.50. Following the completion of the transaction, the chief financial officer directly owned 583,245 shares in the company, valued at $24,904,561.50. This trade represents a 2.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 207,464 shares of company stock valued at $9,157,423 over the last 90 days. Corporate insiders own 13.30% of the company’s stock.

Hedge Funds Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its stake in shares of Scholar Rock by 161.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 713,988 shares of the company’s stock valued at $26,589,000 after purchasing an additional 440,401 shares during the period. Moody Aldrich Partners LLC boosted its position in shares of Scholar Rock by 53.5% in the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock worth $3,789,000 after purchasing an additional 35,481 shares during the last quarter. Norges Bank acquired a new stake in shares of Scholar Rock during the second quarter worth $41,628,000. Voya Investment Management LLC increased its holdings in Scholar Rock by 18.1% in the third quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock valued at $16,503,000 after purchasing an additional 67,839 shares during the last quarter. Finally, HighVista Strategies LLC increased its holdings in Scholar Rock by 90.8% in the third quarter. HighVista Strategies LLC now owns 59,573 shares of the company’s stock valued at $2,218,000 after purchasing an additional 28,343 shares during the last quarter. 91.08% of the stock is owned by institutional investors.

Key Headlines Impacting Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Company resubmitted its FDA filing for apitegromab, prompting a sharp market reaction and setting up a potential regulatory decision around September 2026 — a clear near‑term catalyst if the FDA accepts and completes review. Read More.
• Positive Sentiment: Multiple outlets report the stock surged on the FDA resubmission, reinforcing market optimism that the program’s regulatory pathway is back on track. That reaction increases attention and trading liquidity around SRRK. Read More.
• Positive Sentiment: Analysts are upbeat: Wedbush raised its price target to $58 and kept an “Outperform” rating, implying meaningful upside from current levels — a broker upgrade that can attract more institutional interest. Read More.
• Neutral Sentiment: Company management discussed the BLA resubmission and regulatory progress in a recent transcript; details there may clarify the approval strategy, outstanding FDA questions, and the expected review timeline — useful for assessing probability of approval and timing. Read More.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).